Diabetes pattern on the 75g oral glucose tolerance test is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus

Liver International

Volumn 29, Issue 8, 2009, Pages 1194-1201

  Konishi, Ichiro ^a   Hiasa, Yoichi ^a   Shigematsu, Syuichiro ^a   Hirooka, Masashi ^a   Furukawa, Shinya ^a   Abe, Masanori ^a   Matsuura, Bunzo ^a   Michitaka, Kojiro ^a   Horiike, Norio ^a   Onji, Morikazu ^a  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Diabetes mellitus; Glucose tolerance test; Hepatitis C virus; Hepatocellular carcinoma; Oxidative stress; Tumor necrosis factor alpha

Indexed keywords

ALPHA FETOPROTEIN; ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; CARBONYL DERIVATIVE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER RISK; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; HEPATITIS C; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; COHORT ANALYSIS; COMORBIDITY; GENETICS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEPATITIS C VIRUS; ISOLATION AND PURIFICATION; JAPAN; LIVER; LIVER TUMOR; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; RISK FACTOR;

BLOOD GLUCOSE; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; COMORBIDITY; DIABETES MELLITUS; FATTY LIVER; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; JAPAN; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL;

EID: 70349232293     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.02043.x     Document Type: Article

References (35)

1. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28: 930-8.
2. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687-95.
3. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228-33.
4. Konishi I, Horiike N, Hiasa Y, et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res 2007; 37: 331-6.
5. Caronia S, Taylor K, Pagliaro L, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059-63.
6. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 29: 328-33.
7. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-8.
8. Bruno S, Crosignani A, Maisonneuve P, et al. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350-6.
9. Chiba T, Matsuzaki Y, Abei M, et al.Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol 1996; 31: 552-8.
10. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
11. Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-5.
12. Jungst C, Cheng B, Gehrke R, et al. Oxidative damage is increased in human liver tissue adjacent to hepatocellular carcinoma. Hepatology 2004; 39: 1663-72.
13. El-Serag HB, Tran T, Everhart J.E. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.
14. Fujino Y, Mizoue T, Tokui N, et al. Prospective study of diabetes mellitus and liver cancer in Japan. Diabetes Metab Res Rev 2001; 17: 374-9.
15. Alberti KG, Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetes Med 1998; 15: 539-53.
16. Bonora E, Formentini G, Calcaterra F, et al. HOMAestimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabetes Care 2002; 25: 1135-41.
17. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.
18. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
19. Tazawa J, Maeda M, Nakagawa M, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 710-5.
20. Veldt BJ, Chen W, Heathcote EJ, et al. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-62.
21. Chen CL, Yang HI, Yang WS, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. Gastroenterology 2008; 135: 111-21.
22. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
23. Ikeda K, Arase Y, Saitoh S, et al. Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a largescale long-term study in a single center. Intervirology 2006; 49: 82-90.
24. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
25. Tanaka H, Fujita N, Sugimoto R, et al. Hepatic oxidative DNA damage is associated with increased risk for hepatocellular carcinoma in chronic hepatitis C. Br J Cancer 2008; 98: 580-6.
26. Alamdari DH, Kostidou E, Paletas K, et al. High sensitivity enzyme-linked immunosorbent assay (ELISA) method for measuring protein carbonyl in samples with low amounts of protein. Free Radic Biol Med 2005; 39: 1362-7.
27. Stattin P, Bjor O, Ferrari P, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care 2007; 30: 561-7.
28. Saito K, Inoue S, Saito T, et al. Augmentation effect of postprandial hyperinsulinaemia on growth of human hepatocellular carcinoma. Gut 2002; 51: 100-4.
29. Rose DW, Saltiel AR, Majumdar M, et al. Insulin receptor substrate 1 is required for insulin-mediated mitogenic signal transduction. Proc Natl Acad Sci USA 1994; 91: 797-801.
30. Skolnik EY, Batzer A, Li N, et al. The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 1993; 260: 1953-5.
31. Yoshioka K, Kakumu S, Arao M, et al. Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease. Hepatology 1989; 10: 769-73.
32. Knobler H, Zhornicky T, Sandler A, et al. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol 2003; 98: 2751-6.
33. Maeno T, Okumura A, Ishikawa T, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2003; 18: 1358-63.
34. Muto Y, Sato S, Watanabe A, et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res 2006; 35: 204-14.
35. Sano T, Ozaki K, Kodama Y, et al. Prevention of proliferative changes of forestomach mucosa by blood glucose control with insulin in alloxan-induced diabetic rats. Cancer Sci 2009; 100: 595-600.